PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
completed dosing healthy volunteers and will begin dosing patients in an
on-going phase 1 study of ARC-AAT, the Company’s clinical candidate for
the treatment of liver disease associated with Alpha-1 Antitrypsin
Deficiency (AATD). AATD is a rare genetic disorder that can severely
damage the liver and lungs of affected individuals. The study was
designed to begin dose escalation in healthy volunteers (Part A) and
transition into patients (Part B) when a predefined knockdown target is
achieved. That target is at least 30% reduction of serum AAT levels in 3
subjects or greater than 60% reduction in a single subject. This was met
during the third cohort. All three dose levels tested appear to be
generally well tolerated and the data safety committee has cleared the
study to move into patients with AATD. Dosing in patients may now begin
at the highest dose level used in Part A and then continued dose
escalation may proceed under the protocol. The company expects to
complete the Phase 1 study by the end of 2015.
“We are excited that Part A of the phase 1 study is complete and that we
can now begin studying ARC-AAT directly in patients with PiZZ genotype
AATD,” said Bruce D. Given, M.D., Arrowhead’s Chief Operating Officer.
“The lung disease associated with AATD is frequently treated with AAT
augmentation therapy. However, there is a great need in the field to
identify new treatment options for the AATD-related liver disease.
Currently, the only option for severe cases is liver transplant, with
all of its attendant risks and availability issues. We think ARC-AAT is
a very promising program that may potentially provide a better option
for patients and physicians.”
ARC-AAT is comprised of novel unlocked nucleobase analog containing RNAi
trigger molecules (UNA) that are co-administered with Dynamic
Polyconjugates (DPCs) to enable the escape of the UNA from endosomes.
The ratio of UNA to DPC is 2:1 by weight. In Part A of the study, three
cohorts of six participants each received ARC-AAT at doses of 0.38
mg/kg, 1.0 mg/kg, and 2.0 mg/kg of UNA, and 0.19 mg/kg, 0.5 mg/kg, and
1.0 mg/kg of DPC, respectively.
The Phase 1 trial is a multi-center, randomized, placebo-controlled,
double-blind, single dose-escalation first-in-human study to evaluate
the safety, tolerability and pharmacokinetics of ARC-AAT and the effect
on circulating AAT levels. The study has been enrolling in dose cohorts
of six participants each, with participants randomized at a ratio of 2:1
(active:placebo) to receive a single intravenous injection of either
ARC-AAT or placebo (normal saline). The study consists of two parts;
Part A in healthy volunteers, which has been completed, and Part B to be
conducted in patients with PiZZ genotype AATD. The study evaluates
participants for 28 days following dosing, with additional follow-up if
needed every 2 weeks until AAT levels return to baseline.
“The Alpha-1 Foundation and the entire Alpha-1 community are excited to
see this program move forward,” said John Walsh, president and chief
executive officer of the Alpha-1 Foundation. “We and The Alpha-1
Project, the Foundation’s venture philanthropy arm, will continue to
work closely with Arrowhead on clinical trial recruitment and provide
additional assistance to get this potentially life saving therapy to
adults and children with liver disease due to Alpha-1.”
About Alpha-1 Antitrypsin Deficiency (AATD)
AATD is an autosomal recessive genetic disorder associated with liver
disease in children and adults and pulmonary disease in adults. Alpha-1
antitrypsin is a circulating glycoprotein protease inhibitor of the
serpin family encoded by the AAT gene and primarily synthesized in the
liver. The physiologic function is inhibition of neutrophil proteases to
protect healthy tissues during inflammation and prevent tissue damage.
The Z mutant is the most common disease variant and has a single amino
acid substitution that results in improper protein folding causing
severe impairment of secretion from hepatocytes. This lack of secretion
leads to accumulation of mutant Z-AAT polymers, which form globules in
the hepatocyte endoplasmic reticulum. This triggers continuous
hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of
hepatocellular carcinoma.
In clinical practice, approximately 96-98% of AATD-related disease is
due to the homozygous PiZZ genotype. PiZZ individuals have severe
deficiency of functional AAT leading to pulmonary disease and hepatocyte
injury and liver disease. Lung disease is frequently treated with AAT
augmentation therapy. However, augmentation therapy does nothing to
treat liver disease, and there is no specific therapy for hepatic
manifestations. There is a significant unmet need as liver transplant is
currently the only available treatment for severe liver manifestations.
The mean estimated prevalence of AATD in the U.S is 1 per 3000-5000, or
approximately 100,000 patients. AATD is also an important cause of
pediatric liver disease with an estimated prevalence in children of
approximately 20,000 patients, and 50-80% likely to manifest liver
disease during childhood. It is an orphan disease that appears to be
frequently misdiagnosed or undiagnosed. European prevalence is estimated
to be 1 per 2500.
About ARC-AAT
Arrowhead’s ARC-AAT is being investigated for the treatment of liver
disease associated with Alpha-1 Antitrypsin Deficiency (AATD), a rare
genetic disease that severely damages the liver and lungs of affected
individuals. ARC-AAT employs a novel unlocked nucleobase analog (UNA)
containing RNAi trigger molecule designed for systemic delivery using
the Dynamic Polyconjugate delivery system. ARC-AAT is highly effective
at knocking down the Alpha-1 antitrypsin (AAT) gene transcript and
reducing the hepatic production of the mutant AAT (Z-AAT) protein.
Reduction of liver production of the inflammatory Z-AAT protein, which
is likely a cause of progressive liver disease in AATD patients, is
important as it is expected to halt the progression of liver disease and
potentially allow fibrotic tissue repair. The Company is conducting a
single dose Phase 1 clinical study, with part A in healthy volunteers
and part B in AATD patients.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate™ delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit
http://ir.arrowheadresearch.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including our ability to finance our operations, the
future success of our scientific studies, our ability to successfully
develop drug candidates, the timing for starting and completing clinical
trials, actions of the U.S. Food and Drug Administration (FDA) and
similar global regulatory bodies, rapid technological change in our
markets, challenges to the validity of our intellectual property rights,
and the enforcement of our intellectual property rights. Arrowhead
Research Corporation’s most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q discuss some of the important
risk factors that may affect our business, results of operations and
financial condition. We assume no obligation to update or revise
forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Research Corporation
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Todd James, 646-378-2926
ir@arrowres.com
or
Media:
Russo
Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media